Amyloidosis represents a heterogeneous group of disorders defined by the extracellular deposition of misfolded protein fibrils, which can cause severe impairment in multiple organs. In the context of ...

Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for ...

Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

Bayer to acquire AT-01 & AT-05, investigational molecular imaging agents for the diagnosis of cardiac amyloidosis from Attralus: Berlin, Germany Wednesday, January 14, 2026, 11:00 ...

Lower skeletal muscle mass was associated with an increased risk for short- and long-term mortality in patients with cardiac amyloidosis (CA). This association was particularly strong with ...

ROCHESTER, Minn. — An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for ...

Bayer is acquiring two investigational molecular imaging agents from Attralus for the diagnosis of cardiac amyloidosis.

A new study used data from the UK Biobank to analyze the genes of 469,789 people in the UK and found that one in 1,000 possessed genetic variants with a likely link to cardiac transthyretin (ATTR) ...

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the diagnostic tracers development space. | ...

Please provide your email address to receive an email when new articles are posted on . Cardiac MRI data suggest acoramidis could improve outcomes for people with symptomatic transthyretin amyloid ...

AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis ...

Amyloid heart disease is under-recognized. Early detection and prompt initiation of therapy are critically important. With advances in imaging technology, the diagnosis or surveillance of cardiac ...